Brokerages Set Horizon Therapeutics PLC (NASDAQ:HZNP) Target Price at $37.57
Shares of Horizon Therapeutics PLC (NASDAQ:HZNP) have been assigned an average recommendation of “Buy” from the seventeen brokerages that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $37.57.
Several equities research analysts have recently weighed in on HZNP shares. Stifel Nicolaus increased their target price on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Zacks Investment Research downgraded shares of Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 target price for the company. in a research note on Tuesday, October 29th. Piper Jaffray Companies reiterated a “buy” rating and set a $49.00 target price (up previously from $36.00) on shares of Horizon Therapeutics in a research note on Tuesday, December 24th. Jefferies Financial Group increased their target price on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Finally, Cantor Fitzgerald increased their target price on shares of Horizon Therapeutics from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th.
In related news, EVP Brian K. Beeler sold 9,969 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $32.51, for a total transaction of $324,092.19. Following the completion of the transaction, the executive vice president now directly owns 89,633 shares of the company’s stock, valued at $2,913,968.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeff Kent sold 3,545 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $36.50, for a total transaction of $129,392.50. Following the transaction, the insider now directly owns 121,988 shares of the company’s stock, valued at $4,452,562. The disclosure for this sale can be found here. Insiders have sold 114,413 shares of company stock valued at $4,039,099 over the last three months. 4.10% of the stock is currently owned by corporate insiders.
Shares of HZNP traded up $0.09 during mid-day trading on Friday, hitting $35.93. 590,821 shares of the company’s stock were exchanged, compared to its average volume of 1,472,643. Horizon Therapeutics has a fifty-two week low of $20.05 and a fifty-two week high of $39.10. The firm has a market capitalization of $6.69 billion, a P/E ratio of 97.11, a P/E/G ratio of 1.51 and a beta of 1.07. The business’s 50 day moving average is $36.39 and its two-hundred day moving average is $30.69. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 0.87.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Read More: Why are gap-down stocks important?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.